Mirati’s “Breakthrough” KRASG12C inhibitor, adagrasib, was granted accelerated approval by the FDA in 2022. As it follows Amgen’s first-in-class KRASG12C inhibitor, sotorasib, adagrasib is constantly scrutinized for any evidence it may be different, or better, than sotorasib. This deep dive reviews the current understanding on how adagrasib differs from sotorasib and why, including:
- Is adagrasib really CNS-penetrant?
- What properties would make adagrasib more CNS-penetrant than sotorasib?
- Why does adagrasib appear to be less hepatotoxic with immunotherapy?
- How was adagrasib discovered? and more…
request a trial
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
